Pathos AI seeks $300M at a $3B valuation

Pathos AI is reportedly raising up to $300 million in Series E funding at an approximately $3 billion valuation, according to Axios Pro Rata’s August 6 deal roundup. The round remains unannounced by the company, but the reported valuation would be nearly 88% above the $1.6 billion post-money mark from Pathos’s $365 million Series D in May 2025. Operators tracking AI drug discovery’s shift from model claims to clinical proof should file this as another large capital commitment—not evidence that oncology attrition has improved.